Skip to Main Content

Paper Details

Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer.
NPJ Breast Cancer
11
2022
B, ER, EZH2, Estrogen, Estrogen receptor beta, NF, PRC2, RELA, TNBC, TNBCs, Triple Negative Breast Cancer, breast cancer, cancer, enhancer of zeste homologue 2, p65, patient, polycomb repressive complex 2, triple negative breast cancer, tumor, tumors
Author NameAffiliation
Tanya L HoskinMayo Clinic
Vera J SumanMayo Clinic
Jason S CarrollCancer Research UK Cambridge Research Institute, University of Cambridge
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
James N IngleMayo Clinic
Matthew P GoetzMayo Clinic
  • 1 - 11

Datasets

Release 1.2